The June 1 oral presentation of data from CONVERGE-01 study of CONV01-α will highlight antitumor activity, tolerability and emerging durability in patients whose tumors have progressed following ...
Convergent Therapeutics Inc., a clinical-stage biotechnology company developing next-generation alpha radiopharmaceuticals for cancer, today announced the abstract release for its oral presentation on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results